Pharma sector doubles down on AI to slash costs, timelines
XLV•Pharmaceutical companies are increasingly using AI in research and development, with industry forecasts suggesting machine learning could halve early-stage development timelines and costs within three to five years. On September 29, AbbVie and Valkai announced a partnership to apply AI in clinical development.
1. AI partnerships expand
Pharmaceutical companies are turning to AI tools and automated labs to improve efficiency across research and development. Industry forecasts suggest machine learning could halve early-stage development timelines and costs within the next three to five years.
2. AbbVie adds Valkai deal
AbbVie and Valkai announced a multi-year agreement on September 29 to use AI in selected areas of clinical development, with the aim of improving research efficiency, generating insights faster and helping reduce drug development timelines. The article lists partnerships across the sector, including deals involving Pfizer, Eli Lilly, AstraZeneca and Bristol Myers Squibb.
